From the quarterly report: NOX66 + LuPSMA much better than...

From the quarterly report:

1. NOX66 + LuPSMA much better than LuPSMA alone
   1. Survival data for first 32 patients to be released 13 Feb
2. NOX66 + EBRT responses clearly superior to current standard-of-care
   1. Multi-national, placebo controlled Phase 2b trial being organised
3. NOX expects NOX66 to BECOME the standard-of-care
4. NOX66 being used for compassionate treatment with either EBRT or LuPSMA
   1. Could they charge for this?
5. New drug being developed to treat brain cancer
6. Long-term funding likely to replace convertible notes

NOX66 works.  I expect the share price to increase once the convertible note finance is replaced.